These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26119714)

  • 1. A review of melanized (black) fungal contamination in pharmaceutical products--incidence, drug recall and control measures.
    Vijayakumar R; Saleh Al-Aboody M; Sandle T
    J Appl Microbiol; 2016 Apr; 120(4):831-41. PubMed ID: 26119714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moulds associated with contaminated ocular and injectable drugs: FDA recalls, epidemiology considerations, drug shortages, and aseptic processing.
    Ahearn DG; Stulting RD
    Med Mycol; 2018 Jun; 56(4):389-394. PubMed ID: 29420758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of the order of incubation for the recovery of bacteria and fungi from pharmaceutical-grade cleanrooms.
    Sandle T
    Int J Pharm Compd; 2014; 18(3):242-7. PubMed ID: 25306772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different incubation conditions for microbiological environmental monitoring.
    Gordon O; Berchtold M; Staerk A; Roesti D
    PDA J Pharm Sci Technol; 2014; 68(5):394-406. PubMed ID: 25336415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different fungal agar for the environmental monitoring of pharmaceutical-grade cleanrooms.
    Gebala B; Sandle T
    PDA J Pharm Sci Technol; 2013; 67(6):621-33. PubMed ID: 24265303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the microbiological quality of pharmaceutical excipients.
    Cundell AM
    PDA J Pharm Sci Technol; 2005; 59(6):381-95. PubMed ID: 16471425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbial diversity in pharmaceutical product recalls and environments.
    Jimenez L
    PDA J Pharm Sci Technol; 2007; 61(5):383-99. PubMed ID: 18047177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fungal growth pattern, sources and factors of mould contamination in a dry-cured meat production facility.
    Asefa DT; Kure CF; Gjerde RO; Omer MK; Langsrud S; Nesbakken T; Skaar I
    Int J Food Microbiol; 2010 Jun; 140(2-3):131-5. PubMed ID: 20442004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment.
    Tanyous JN
    PDA J Pharm Sci Technol; 2019; 73(2):204-210. PubMed ID: 30361288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fungi associated with drug recalls and rare disease outbreaks.
    Ahearn DG; Doyle Stulting R
    J Ind Microbiol Biotechnol; 2014 Nov; 41(11):1591-7. PubMed ID: 25173741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aseptic processing contamination case studies and the pharmaceutical quality system.
    Friedman RL
    PDA J Pharm Sci Technol; 2005; 59(2):118-26. PubMed ID: 15971544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports.
    Almutairi M; Algabbani A; Alasiri A; Alhomaidan A; Alqahtani AS
    Ther Innov Regul Sci; 2024 Jul; 58(4):689-695. PubMed ID: 38546962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Types of microbial contaminants in pharmaceutical raw materials].
    Martínez-Bermúdez A; Rodríguez-de Lecea J; Soto-Esteras T; Vázquez-Estévez C; Chena-Cañete C
    Rev Latinoam Microbiol; 1991; 33(2-3):153-7. PubMed ID: 1670480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mould and mycotoxin contamination of medicinal materials].
    Qin X; Guo S
    Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3397-401. PubMed ID: 22368843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microbiological in-process control in drug manufacture].
    Seyfarth VH
    Arzneimittelforschung; 1985; 35(1A):205-16. PubMed ID: 4039162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance.
    Bercu JP; Sharnez R; Dolan DG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):157-61. PubMed ID: 22921793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoor fungal contamination: health risks and measurement methods in hospitals, homes and workplaces.
    Méheust D; Le Cann P; Reboux G; Millon L; Gangneux JP
    Crit Rev Microbiol; 2014 Aug; 40(3):248-60. PubMed ID: 23586944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disinfectants as an aid for good manufacturing practice in the pharmaceutical industry.
    Wallhäusser KH
    J Pharm Belg; 1981; 36(5):283-97. PubMed ID: 7310623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.